Document

A new study (Edelman 2022) adds to the evidence around use of LNG-EC by those with higher weight/BMI but does not give a clear enough picture to inform any change in guidance.

A recently-published literature review considers the evidence around mechanism of action of levonorgestrel oral emergency contraception (LNG-EC). The findings support current FSRH guidance on emergency contraception, and are reassuring for those with ethical concerns about post-ovulation effects.

This FSRH Satement notes the availability and dispensive of the combined vaginal contraceptive rings in the UK.

The Clinical Effectiveness Unit have had a number of recent queries around the extended use of LARC during COVID19. We would like to remind Members that extended use of LARC was recommended only when health risk associated with COVID19 transmission was at its highest.

Benilexa® (Gedeon Richter) - a 52mg levonorgestrel-releasing intrauterine system (LNG-IUS) with a reloadable one-handed insertion device - is now available in the UK. Benilexa is licensed for 6 years of use for contraception. It is not licensed for endometrial protection as part of HRT. This FSRH CEU Resource provides a table which compares the product characteristics of LNG-IUS devices currently available in the UK, Benilexa®, Levosert®, Mirena®, Kyleena® and Jaydess®.

This FSRH Statement reviews two desogestrel 75mcg progestogen-only pill (POP) available over-the-counter as Pharmacy Medicines.

Statement from the Royal College of Obstetricians & Gynaecologists (RCOG), the Faculty of Sexual and Reproductive Healthcare and the British Society of Abortion Care Providers (BSACP) regarding the advent of telemedical abortion care and the safeguarding of young people.

Recent media reports have highlighted cases of individuals who have experienced distressing intrauterine contraception (IUC) fitting. Read and download the FSRH statement on pain associated with intrauterine contraception.

This statement relates to a field safety notice released by intrauterine device manufacturer Eurogine in 2018 and 2019.

Sexually active women of reproductive age with eating disorders require effective contraception despite the fact that amenorrhoea and anovulation are common in this population. This statement provides clinicians with a resource for best helping women with eating disorders choose the most appropriate and acceptable contraception for them. Download and save the document here.